Immix Biopharma (IMMX) to Release Earnings on Friday

Key Points

• Immix Biopharma (IMMX) is set to announce its Q2 2025 earnings on August 11th, with analysts projecting a loss of ($0.21) per share for the quarter.
• The company's stock price recently reached $2.66, with a market capitalization of $74.02 million and year-to-date trading activity indicating a range between $1.26 and $3.20.
• HC Wainwright maintains a "buy" rating on IMMX with a price target of $7.00, while Wall Street Zen has adjusted its rating to "hold."

Immix Biopharma (NASDAQ:IMMX - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.01). On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Price Performance

Shares of IMMX stock remained flat at $2.39 during trading hours on Friday. 117,194 shares of the company were exchanged, compared to its average volume of 278,265. Immix Biopharma has a 1-year low of $1.26 and a 1-year high of $3.20. The company's fifty day simple moving average is $2.53 and its 200-day simple moving average is $2.08. The company has a market cap of $66.63 million, a price-to-earnings ratio of -3.41 and a beta of 0.28.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Immix Biopharma in a research note on Wednesday, June 4th. Wall Street Zen raised shares of Immix Biopharma to a "hold" rating in a research note on Friday, June 27th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.